Prollenium® Medical Technologies
Prollenium Medical Technologies, founded in 2002 by Ario Khoshbin and based in Richmond Hill, Ontario, Canada, is a leading company in the field of medical aesthetics. The company specializes in the research, development, and manufacturing of high-quality hyaluronic acid (HA) dermal fillers. Prollenium's flagship product line, Revanesse®, is known for its advanced HA formulations and is used by aesthetic professionals worldwide to provide natural-looking facial enhancements. Prollenium is dedicated to innovation, continuously investing in research and development to create cutting-edge products that meet the evolving needs of healthcare practitioners and patients. The company's commitment to quality is reflected in its state-of-the-art manufacturing facilities, where each product undergoes rigorous testing to ensure safety and efficacy. In addition to its industry-leading dermal fillers, Prollenium is known for its customer-focused approach, building strong relationships with healthcare professionals through education, training, and support. With a global presence and a reputation for excellence, Prollenium Medical Technologies remains at the forefront of the medical aesthetics industry.
Prollenium® Medical Technologies Introduction
Prollenium® Medical Technologies is a Canadian-based company focused exclusively on the research and manufacturing of dermal fillers. The company’s significant commitment to R&D allows to continuously optimize their processes and creates a deep product pipeline. Their most known brand is Revanesse®, which offers a full range of dermal fillers that leverage state-of-the-art production methods, optimal ingredients and rigorous quality testing to provide remarkable results.
Prollenium® Medical Technologies is a registered ISO 13485:2016 company, and one of a select group of FDA-approved facilities.